VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need.
By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide.
Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.
With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.
Company Details
- Employees
- 92
- Founded
- -
- Address
- Science Park, Matrix Innovation Center 408,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.vectorytx.com
- HQ
- Amsterdam
Vectory Questions
Vectory's website is http://www.vectorytx.com
Vectory's LinkedIn profile is https://nl.linkedin.com/company/vectorytx1
Vectory has
92 employees.
View email and phone details for 92
employees at Vectory.
Vectory's industry is
Biotechnology Research
Vectory's top competitors are
Genmab,
Leyden Labs,
Scenic Biotech,
Lava Therapeutics N.v.,
Galapagos,
Uniqure,
Neogene Therapeutics,
Merus N.v.,
Batavia Biosciences,
Proqr Therapeutics.
Vectory's categories are Biotechnology Research
Vectory's founding year is 2020
